PT  - JOURNAL ARTICLE
AU  - Venkateswaran, Suresh
AU  - Somineni, Hari K
AU  - Matthews, Jason D.
AU  - Kilaru, Varun
AU  - Hyams, Jeffrey S
AU  - Denson, Lee A
AU  - Kellamayer, Richard
AU  - Gibson, Greg
AU  - Cutler, David J
AU  - Conneely, Karen N
AU  - Smith, Alicia K
AU  - Kugathasan, Subra
TI  - Longitudinal DNA Methylation Profiling of the Rectal Mucosa Identifies Cell-specific Signatures of Disease Status, Severity and Clinical Outcomes in Ulcerative Colitis
AID  - 10.1101/2022.01.28.22269598
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.28.22269598
4099  - http://medrxiv.org/content/early/2022/01/30/2022.01.28.22269598.short
4100  - http://medrxiv.org/content/early/2022/01/30/2022.01.28.22269598.full
AB  - In peripheral blood, DNA methylation (DNAm) patterns in inflammatory bowel disease patients reflect inflammatory status rather than disease status. Here, we studied DNAm in diseased rectal mucosa from ulcerative colitis (UC) patients, conducting a cell-type-specific EWAS in epithelial, immune and fibroblast cells to understand DNAm changes across disease states, course, and clinical outcomes. At diagnosis, rectal mucosa in UC exhibited a lower proportion of epithelial cells and fibroblasts, and higher proportion of immune cells, along with 3504, 910, and 2279 altered DNAm sites as detected in our cell-specific EWAS, respectively. While treatment had significant effects on DNAm of immune cells, its effects on fibroblasts and epithelial cells were attenuated. Those requiring colectomy exhibited cell composition and DNAm patterns at follow-up more like disease onset than patients who did not require colectomy. Collectively DNAm and gene expression analysis suggest that targeting epithelial genes involved in barrier function may improve clinical outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH), under grant numbers R21DK119997 (SK) and 5U01DK095745 (LAD and JH). This work was also supported by a research initiative grant (RISK) from the Crohns and Colitis Foundation, New York, NY.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Emory University gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe DNAm data for all the 369 rectal biopsy samples included in this study have been deposited in the Gene Expression Omnibus (GEO) and are accessible through GEO series accession GSE18506. To review GEO accession GSE185061: Go to https://nam11.safelinks.protection.outlook.com/?url=www.ncbi.nlm.nih.gov%2Fgeo%2Fquery%2Facc.cgi%3Facc%3DGSE185061&data=04%7C01%7Csuresh.venkateswaran%40emory.edu%7C608f82f0576743c3699708d9dc2a5235%7Ce004fb9cb0a4424fbcd0322606d5df38%7C0%7C0%7C637782896589960813%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=q8AL8lh3%2BJoLySJkL%2FaahHLThr3lil6NXNfSxMwxaAo%3D&reserved=0 Enter token abylkamahxcjlwp into the box(ACC)Accuracies(AUC)Area Under the Curve(DNAm)DNA Methylation(EWAS)Epigenome-Wide Association Studies(FDR)False Discovery Rate(GO)Gene Ontology(IBD)Inflammatory Bowel Disease(PUCAI)Pediatric Ulcerative Colitis Activity Index(PROTECT)Predicting Response to Standardized Pediatric Colitis Therapy(PCs)Principle Components(RISK)Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children with Crohn’s Disease(UC)Ulcerative Colitis